Pancreatic Atrophy in Hepatocellular Carcinoma Patients Receiving Long-Term Treatment with Sorafenib

Publisher： Karger

E-ISSN： 1423-0232|89|2|88-94

ISSN： 0030-2414

Source： Oncology, Vol.89, Iss.2, 2015-04, pp. : 88-94

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Long-Term Outcomes of Hepatitis-C-Infected Patients Achieving a Sustained Virological Response and Undergoing Radical Treatment for Hepatocellular Carcinoma

By  

Oncology, Vol. 90, Iss. 3, 2016-02 ,pp. : 167-175

Karger

Access to resources Recommend Favorite

Sunitinib in Patients with Advanced Hepatocellular Carcinoma after Progression under Sorafenib Treatment

By  

Oncology, Vol. 79, Iss. 1-2, 2010-11 ,pp. : 85-92

Karger

Access to resources Recommend Favorite

Characteristics of Long-Term Survivors following Sorafenib Treatment for Advanced Hepatocellular Carcinoma: Report of a Workshop at the 50th Annual Meeting of the Liver Cancer Study Group of Japan

By  

Oncology, Vol. 87, Iss. 1, 2014-11 ,pp. : 104-109

Karger

Access to resources Recommend Favorite

Outcomes of elderly patients with HCC

By  

HEPATOLOGY RESEARCH, Vol. 44, Iss. 9, 2014-09 ,pp. : 975-982

John Wiley & Sons Inc

Access to resources Recommend Favorite

Economic evaluation of sorafenib in the treatment of hepatocellular carcinoma in Canada

By Muszbek Noemi   Shah Sonalee   Carroll Stuart   McDonald Heather   Dale Peter   Maroun Jean   Knox Jennifer  

Current Medical Research and Opinion, Vol. 24, Iss. 12, 2008-12 ,pp. : 3559-3569

Informa Healthcare

Access to resources Recommend Favorite